HDAC9 and ovarian cancer: Therefore, HDAC inhibitors can be potentially employed to promote histone acetylation levels and to therefore elevate RGS2 expression levels, providing with the evidence that inhibition of histone deacetylase activity may be a new therapeutic target for epithelial ovarian cancers in clinic, particularly the platinum-resistant ovarian cancer [27].